Floatz logo

Cyclophosphamide

B-Cell Neoplasm

University Hospital, Basel, SwitzerlandSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the B-Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Zanubrutinib
Curis, Inc.
Phase 2BB
Adriamycin
Curis, Inc.
Phase 2BB
Prednisone
Curis, Inc.
Phase 2BB
Rituximab
Curis, Inc.
Phase 2BB
Lenalidomide
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
mycosis fungoidesActive
BBB
Indicative · Phase 4
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →